Trial Profile
A Phase I/II Clinical Trial of Nivolumab in Progressive/Relapsed Pediatric Solid Tumors
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Cyclophosphamide
- Indications Solid tumours
- Focus Therapeutic Use
- 28 Sep 2016 New trial record